Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Describing Cognitive Decline of Patients at the Mild or Moderate Stages of Alzheimer's Disease Using the Standardized MMSE

  • Alexandra Ward, J. Jaime Caro, Heather Kelley, Andrew Eggleston, William Molloy
  • Journal:
    International Psychogeriatrics / Volume 14 / Issue 3 / September 2002
    Published online by Cambridge University Press:
    10 January 2005, pp. 249-258

  • Objective: To describe the progression of patients with mild or moderate Alzheimer's disease (AD) to a severe stage using the Standardized Mini-Mental State Examination (SMMSE). Methods: A cohort of 206 patients was stratified according to their baseline SMMSE scores: mild (19–24) and moderate (10–18). Proportional hazards analyses were used to determine the hazard of switching into a severe stage, defined as SMMSE score < 10. Results: Among patients at the mild stage, 25% reached the severe stage within 2.6 years, and in the moderate group within 1.5 years. Patients with hallucinations at the mild stage experienced more rapid decline. The previous rate of decline was also found to be an important predictor. At the moderate stage, key predictors were lower SMMSE score and longer time since onset. Conclusions: Current SMMSE scores with other clinical details can be used to advise patients and caregivers about the expected progression of AD.